QCG
KPTI icon

Quadrant Capital Group’s Karyopharm Therapeutics KPTI Stock Holding History

Quadrant Capital Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed – – 2722
2022
Q2 		$0 Hold
6
– – ﹤0.01% 2635
2022
Q1 		$1K Sell
6
-23
-79% -$2.87K ﹤0.01% 2328
2021
Q4 		$3K Buy
29
+23
+383% +$2.29K ﹤0.01% 2039
2021
Q3 		$1K Buy
6
+4
+200% +$415 ﹤0.01% 2330
2021
Q2 		$0 Buy
+2
New +$290 ﹤0.01% 2480

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Quadrant Capital Group's KPTI Position: Q3 2022 in Review

Quadrant Capital Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 6 shares.

Quadrant Capital Group first reported a position in KPTI in Q2 2021 and held it in 5 quarters. The position peaked at $3K in Q4 2021. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Quadrant Capital Group reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 6 Karyopharm Therapeutics shares in Q3 2022.
  • Quadrant Capital Group first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 5 quarters.
  • Quadrant Capital Group's Karyopharm Therapeutics position peaked at $3K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Quadrant Capital Group's 13F filing for Q3 2022, filed 10 Nov 2022.